• Molecular NameCeftizoxime
  • SynonymCeftizoxima [inn-spanish]; Ceftizoximum [inn-latin]
  • Weight383.409
  • Drugbank_IDDB01332
  • ACS_NO68401-81-0
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-0.44
  • pka2.95
  • LogD (pH=7, predicted)-4.34
  • Solubility (experiment)Freely soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.52
  • LogSw (predicted, AB/LogsW2.0)3.38
  • Sw (mg/ml) (predicted, ACD/Labs)0.14
  • No.of HBond Donors4
  • No.of HBond Acceptors10
  • No.of Rotatable Bonds5
  • TPSA200.75
  • StatusFDA approved
  • Administrationintramuscular
  • PharmacologyA parenteral third-generation cephalosporin.
  • Absorption_value72.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding28.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmCeftizoxime is not metabolized, and is excreted virtually unchanged by the kidneys in 24 hours. This provides a high urinary concentration.
  • Half life1.7 hours was observed after IV or IM administration
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most frequent adverse reactions (greater than 1 % but less than 5%) are: Hypersensitivity: Rash, pruritus, fever. Hepatic: Transient elevation in AST (SGOT), ALT (SGPT), and alkaline phosphatase. Hematologic: Transienteosinophilia, thrombocytosis. Some individuals have developed a positive Coombs test. Local?Injection site: Burning, cellulitis, phlebitis with IV administration, pain, induration, tenderness, paresthesia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A